Heat Biologics, Inc. HTBX
Set alert
2.38 +2.38 —
Day range unavailable
52-week range unavailable
- Open
- —
- Prev close
- 0.00
- Mkt cap
- 61.07M
- Vol
- 0
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- —
- High
- —
- Forward P/E
- -1.62
- Beta
- 0.30
- Short ratio
- 0.00
- Inst. own
- 10.76%
- Dividend
- 0.00
- Ex-div date
- Earnings
- May 4, 2022
- 50-d avg
- 2.57
- 200-d avg
- 4.11
- 1y target
- 11.38
6M chart
Events in this range
- Nov 10, 2021Earnings: —; estimate -0.29; surprise —%
- Mar 14, 2022Earnings: —; estimate -0.31; surprise —%
Signals (22)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Apr 20, 2022 | 4 years ago |
| SMA: Bearish | Apr 19, 2022 | 4 years ago |
| SMA: Bullish | Apr 18, 2022 | 4 years ago |
| MACD: Sell Signal | Apr 8, 2022 | 4 years ago |
| SMA: Bullish | Mar 22, 2022 | 4 years ago |
| MACD: Buy Signal | Mar 17, 2022 | 4 years ago |
| MACD: Sell Signal | Mar 14, 2022 | 4 years ago |
| RSI: Oversold | Mar 14, 2022 | 4 years ago |
| MACD: Buy Signal | Mar 10, 2022 | 4 years ago |
| MACD: Sell Signal | Mar 4, 2022 | 4 years ago |
| MACD: Buy Signal | Mar 3, 2022 | 4 years ago |
| MACD: Sell Signal | Mar 2, 2022 | 4 years ago |
| MACD: Buy Signal | Feb 28, 2022 | 4 years ago |
| MACD: Sell Signal | Feb 25, 2022 | 4 years ago |
| RSI: Oversold | Jan 20, 2022 | 4 years ago |
| MACD: Buy Signal | Jan 10, 2022 | 4 years ago |
| MACD: Sell Signal | Dec 28, 2021 | 4 years ago |
| RSI: Oversold | Dec 27, 2021 | 4 years ago |
| RSI: Oversold | Dec 22, 2021 | 4 years ago |
| RSI: Oversold | Dec 16, 2021 | 4 years ago |
Newest 20 of 22.
Analyst view
Consensus: buy
Buy
Price target (mean) 11.38 +378.2% upside
Now 2.38
- Target (low)
- 8.00
- Target (mean)
- 11.38
- Target (high)
- 15.50
Ratings (0m) 2 2 buy · 0 hold · 0 sell
- Strong buy1
- Buy1
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 2
- 1 month ago 4
- 2 months ago 4
- 3 months ago 1
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.49 | -0.53 – -0.46 | -0.31 | -58.1% | 212.00K | -60.7% | 2 |
| Next quarter | -0.47 | -0.53 – -0.42 | -0.26 | -80.8% | 1.40M | 0.0% | 2 |
| Current year | -1.71 | -2.10 – -1.30 | -1.41 | -21.3% | 4.43M | +109.7% | 3 |
| Next year | -1.47 | -1.75 – -1.32 | -1.71 | +14.0% | 4.67M | +5.4% | 3 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 3, 2021 | Cantor Fitzgerald | Initiated | — | Overweight |
| Oct 14, 2020 | B. Riley FBR | Initiated | — | Buy |
| Feb 6, 2020 | Maxim Group | Initiated | — | Buy |
| Jul 30, 2019 | Brookline Capital | Initiated | — | Buy |
| Jun 26, 2018 | H.C. Wainwright | Initiated | — | Buy |
| Jun 20, 2016 | Roth Capital | Initiated | — | Buy |
| Feb 4, 2016 | Cantor Fitzgerald | Downgrade | Buy | Speculative Buy |
| May 26, 2015 | H.C. Wainwright | Initiated | — | Buy |
| Sep 23, 2013 | Aegis Capital | Initiated | — | Buy |
| Sep 18, 2013 | Aegis Capital | Initiated | — | Buy |
| Sep 3, 2013 | Canaccord Genuity | Initiated | — | Buy |